000196522 001__ 196522
000196522 005__ 20190812205739.0
000196522 0247_ $$2doi$$a10.1117/12.60952
000196522 037__ $$aCONF
000196522 245__ $$aClinical LIF pharmacokinetic measurements with Photofrin II for optimizing the photodetection of early cancer
000196522 260__ $$c1992
000196522 269__ $$a1992
000196522 336__ $$aConference Papers
000196522 520__ $$aNew results are presented on the pharmacokinetics of the fluorescing fraction of Photofrin II in patients with an early cancer in the oesophagus or the buccal cavity. The light-induced fluorescence signal shows a relatively high contrast between tumor and surrounding normal tissue at short times after i.v. injection. The magnitude of this contrast appears to correlate with the staging of the cancer, the more invasive tumors showing the highest contrast. Some early results on the ex vivo fluorescence analysis of biopsies taken on patients injected with the new sensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC) demonstrate the selectivity of this efficient second generation photosensitizer for advanced lung cancer. mTHPC appears to have good properties for photodetection and has a rather high rate of photobleaching. The significant of the latter is discussed in relation to simplifying light application in PDT.
000196522 700__ $$aBraichotte, D.
000196522 700__ $$0241203$$g106697$$aWagnieres, G.
000196522 700__ $$aPhilippoz, J. M.
000196522 700__ $$aBays, Roland
000196522 700__ $$aRis, H.-B.
000196522 700__ $$aMonnier, Philippe
000196522 700__ $$aChatelain, Andre
000196522 700__ $$aBergh, Hubert$$g106613$$0240886
000196522 773__ $$j1645$$tProceedings of SPIE - The International Society for Optical Engineering$$q229-240
000196522 909C0 $$pLPAS$$0252376$$xU10271
000196522 909CO $$pconf$$ooai:infoscience.tind.io:196522
000196522 917Z8 $$x171848
000196522 937__ $$aEPFL-CONF-196522
000196522 973__ $$rNON-REVIEWED$$sPUBLISHED$$aEPFL
000196522 980__ $$aCONF